Last reviewed · How we verify

Islets of Langerhans transplantation

CellTrans Inc. · Phase 3 active Biologic

Islets of Langerhans transplantation is a Cell therapy / Allogeneic transplant Biologic drug developed by CellTrans Inc.. It is currently in Phase 3 development for Type 1 diabetes mellitus with severe hypoglycemia unawareness or brittle diabetes, Type 1 diabetes with impaired kidney function (simultaneous pancreatic islet and kidney transplant). Also known as: Islets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®).

Islet transplantation restores functional insulin-producing beta cells to the pancreas, enabling endogenous insulin secretion and glucose homeostasis in patients with type 1 diabetes.

Islet transplantation restores functional insulin-producing beta cells to the pancreas, enabling endogenous insulin secretion and glucose homeostasis in patients with type 1 diabetes. Used for Type 1 diabetes mellitus with severe hypoglycemia unawareness or brittle diabetes, Type 1 diabetes with impaired kidney function (simultaneous pancreatic islet and kidney transplant).

At a glance

Generic nameIslets of Langerhans transplantation
Also known asIslets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®), Etanercept(Enbrel®)
SponsorCellTrans Inc.
Drug classCell therapy / Allogeneic transplant
ModalityBiologic
Therapeutic areaEndocrinology / Diabetes
PhasePhase 3

Mechanism of action

This procedure involves isolation and transplantation of pancreatic islets (clusters of insulin-secreting beta cells) from a donor pancreas into a recipient with type 1 diabetes. The transplanted islets engraft in the recipient's liver or other sites and begin producing insulin in response to blood glucose levels, potentially eliminating the need for exogenous insulin therapy. Success requires immunosuppression to prevent rejection of the allogeneic tissue.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Islets of Langerhans transplantation

What is Islets of Langerhans transplantation?

Islets of Langerhans transplantation is a Cell therapy / Allogeneic transplant drug developed by CellTrans Inc., indicated for Type 1 diabetes mellitus with severe hypoglycemia unawareness or brittle diabetes, Type 1 diabetes with impaired kidney function (simultaneous pancreatic islet and kidney transplant).

How does Islets of Langerhans transplantation work?

Islet transplantation restores functional insulin-producing beta cells to the pancreas, enabling endogenous insulin secretion and glucose homeostasis in patients with type 1 diabetes.

What is Islets of Langerhans transplantation used for?

Islets of Langerhans transplantation is indicated for Type 1 diabetes mellitus with severe hypoglycemia unawareness or brittle diabetes, Type 1 diabetes with impaired kidney function (simultaneous pancreatic islet and kidney transplant).

Who makes Islets of Langerhans transplantation?

Islets of Langerhans transplantation is developed by CellTrans Inc. (see full CellTrans Inc. pipeline at /company/celltrans-inc).

Is Islets of Langerhans transplantation also known as anything else?

Islets of Langerhans transplantation is also known as Islets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®), Etanercept(Enbrel®).

What drug class is Islets of Langerhans transplantation in?

Islets of Langerhans transplantation belongs to the Cell therapy / Allogeneic transplant class. See all Cell therapy / Allogeneic transplant drugs at /class/cell-therapy-allogeneic-transplant.

What development phase is Islets of Langerhans transplantation in?

Islets of Langerhans transplantation is in Phase 3.

What are the side effects of Islets of Langerhans transplantation?

Common side effects of Islets of Langerhans transplantation include Graft failure / loss of insulin independence, Immunosuppression-related infections, Immunosuppression-related malignancy, Bleeding at transplant site, Portal vein thrombosis, Hyperglycemia recurrence.

Related